Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Eli Lilly and Company: Clinical Trials & FDA Approval Profile

Eli Lilly and Company (Indianapolis, IN) sponsors 334 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 146 active protocols (77 recruiting now), 156 completed protocols, and 88 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.6%
Median Closed Enrollment vs National (145 pts)312 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Eli Lilly and Company
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)334
Active Pipeline (Recruiting Now)146 (77)
Completed vs Stopped Early156 / 32 (9.6%)
Median Closed Actual Enrollment312 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals88 (16 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Eli Lilly and Company
Hospital Research SiteLocationShared Protocols
Hospital Universitari Vall d'HebronBarcelona56
National Taiwan University HospitalTaipei56
Severance Hospital, Yonsei University Health SystemSeoul, Other53

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Eli Lilly and Company
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07218380A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractPhase IIIRECRUITING
NCT07613294A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at HighPhase IIIRECRUITING
NCT07219953A Study of Brenipatide in Participants With Alcohol Use DisorderPhase IIIRECRUITING
NCT07589608A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OvPhase IIRECRUITING
NCT05254743A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLLPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Eli Lilly and Company Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI